3,219 Shares in Axsome Therapeutics, Inc. $AXSM Bought by Leonteq Securities AG

Leonteq Securities AG purchased a new position in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM) during the 4th quarter, Holdings Channel.com reports. The firm purchased 3,219 shares of the company’s stock, valued at approximately $588,000.

Several other hedge funds and other institutional investors have also recently bought and sold shares of AXSM. Optiver Holding B.V. raised its stake in Axsome Therapeutics by 82.3% during the 3rd quarter. Optiver Holding B.V. now owns 288 shares of the company’s stock worth $35,000 after acquiring an additional 130 shares in the last quarter. Essex Investment Management Co. LLC acquired a new stake in Axsome Therapeutics during the 3rd quarter worth $38,000. Advisory Services Network LLC acquired a new stake in Axsome Therapeutics during the 3rd quarter worth $40,000. UMB Bank n.a. raised its stake in Axsome Therapeutics by 214.4% during the 3rd quarter. UMB Bank n.a. now owns 371 shares of the company’s stock worth $45,000 after acquiring an additional 253 shares in the last quarter. Finally, GAMMA Investing LLC raised its stake in Axsome Therapeutics by 65.4% during the 4th quarter. GAMMA Investing LLC now owns 268 shares of the company’s stock worth $49,000 after acquiring an additional 106 shares in the last quarter. 81.49% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Axsome Therapeutics

In other Axsome Therapeutics news, COO Mark L. Jacobson sold 35,378 shares of Axsome Therapeutics stock in a transaction on Thursday, February 26th. The shares were sold at an average price of $161.88, for a total value of $5,726,990.64. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, Director Mark Coleman sold 25,000 shares of Axsome Therapeutics stock in a transaction on Thursday, February 26th. The shares were sold at an average price of $161.11, for a total transaction of $4,027,750.00. Following the completion of the transaction, the director owned 47,140 shares in the company, valued at approximately $7,594,725.40. This represents a 34.65% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders have sold 72,628 shares of company stock worth $12,205,662. 20.60% of the stock is owned by company insiders.

Axsome Therapeutics Trading Up 1.0%

NASDAQ AXSM opened at $235.97 on Friday. The company has a debt-to-equity ratio of 2.27, a quick ratio of 1.32 and a current ratio of 1.39. The firm has a market cap of $12.14 billion, a PE ratio of -63.26 and a beta of 0.59. Axsome Therapeutics, Inc. has a one year low of $96.09 and a one year high of $236.84. The firm’s fifty day moving average is $187.84 and its two-hundred day moving average is $171.84.

Axsome Therapeutics (NASDAQ:AXSM) last posted its quarterly earnings data on Monday, May 4th. The company reported ($1.26) EPS for the quarter, missing analysts’ consensus estimates of ($0.85) by ($0.41). The business had revenue of $191.20 million during the quarter, compared to analyst estimates of $191.10 million. Axsome Therapeutics had a negative net margin of 26.59% and a negative return on equity of 267.16%. The business’s revenue was up 57.4% compared to the same quarter last year. Analysts expect that Axsome Therapeutics, Inc. will post -2.14 earnings per share for the current year.

Analysts Set New Price Targets

AXSM has been the topic of several research analyst reports. Oppenheimer set a $280.00 price target on shares of Axsome Therapeutics in a research note on Monday, May 4th. Morgan Stanley lifted their price target on shares of Axsome Therapeutics from $217.00 to $242.00 and gave the stock an “equal weight” rating in a research note on Tuesday, May 5th. HC Wainwright lifted their price target on shares of Axsome Therapeutics from $270.00 to $290.00 and gave the stock a “buy” rating in a research note on Tuesday, May 5th. Cantor Fitzgerald reiterated an “overweight” rating and set a $272.00 price target on shares of Axsome Therapeutics in a research note on Monday, May 4th. Finally, Royal Bank Of Canada lifted their price target on shares of Axsome Therapeutics from $242.00 to $302.00 and gave the stock an “outperform” rating in a research note on Tuesday, May 5th. One investment analyst has rated the stock with a Strong Buy rating, eighteen have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Axsome Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $251.26.

Axsome Therapeutics Company Profile

Axsome Therapeutics, Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for central nervous system (CNS) disorders. The company focuses on small-molecule drugs designed to address unmet medical needs in areas such as depression, migraine, narcolepsy and fibromyalgia. Axsome employs a precision medicine approach, leveraging pharmacologic innovation to target underlying mechanisms of disease and improve patient outcomes.

Axsome’s pipeline includes several late-stage and approved product candidates.